Amira Files to Start Clinical Trial

Xconomy San Diego — 

San Diego-based Amira Pharmaceuticals, the developer of treatments for lung diseases, said today it has filed an application to the FDA to start clinical trials of a new drug for fibrotic disorders. The company is seeking to run tests in healthy volunteers on AM152, an experimental blocker of a target called LPA1.